Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
SLS · against 428 other Healthcare companies of similar size
Ranked #294 of 429 · scores higher than 31% of peers
Bars: peers in each 10-point band of the valuation score34 peers with a valuation score of 30–39, including SLS · Click a bar to see the companies
Mainly because of its earnings yield, which is weaker than most Healthcare peers.
| Metric | SLS | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 418 reported | -2.7% | 1.8% | 29% | 30% | |
| EBITDA yieldHigher is better · 428 reported | Not reported | 4.5% | — | — | 50% |
| Free cash flow yieldHigher is better · 196 reported | -1.6% | -0.3% | 44% | 20% | |
| Book yieldHigher is better · 420 reported | 7.7% | 36.3% | 10% | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 12.9B HKD (≈$1.7B) | 99 | 83 | |
| 1 | 226.3B JPY (≈$1.5B) | 99 | 77 | |
| 1 | 40.2B MXN (≈$2.2B) | 99 | 71 | |
| 289 | 3.1B USD | 36 | 53 | |
| 289 | 1.9B USD | 36 | 47 | |
| 294 | 1.2B USD | 33 | ||
| 294 | 2.2B USD | 33 | 48 | |
| 294 | 1.8B USD | 33 | ||
| 294 | 3.3B USD | 33 | 39 | |
| 298 | 1.86T KRW (≈$1.3B) | 32 | 43 | |
| 298 | 1.1B USD | 32 | 61 | |
| 298 | 1.9B NZD (≈$1.1B) | 32 | 42 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score